zoledronic acid has been researched along with Osteosarcoma in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (26.09) | 29.6817 |
| 2010's | 37 (53.62) | 24.3611 |
| 2020's | 14 (20.29) | 2.80 |
| Authors | Studies |
|---|---|
| Damron, TA | 1 |
| Bryan, JN; Ehling, TJ; Flesner, BK; Keys, DA; Lattimer, JC; Maitz, CA; Moore, M; Norquest, CJ | 1 |
| Jeong, YH; Ko, Y; Lee, JA | 1 |
| Almond, GT; Bergman, NS; Lindley, SES; Matz, BM; Smith, AA; Smith, AN | 1 |
| Christou, A; Ferreira, N; Sophocleous, A | 1 |
| Haonan, L; Jiacong, H; Keng, C; Qirui, Y; Yan, C; Yichang, S | 1 |
| Borges, R; de Araujo, DR; Justo, GZ; Machado, J; Marchi, J; Pelosine, AM; Schneider, JF; Souza, ACS; Zambanini, T | 1 |
| Dash, M; Dash, P; Piras, AM; Prasad Panda, G; Samal, S | 1 |
| Lin, CW; Lu, EW; Lu, KH; Yang, JS; Yang, SF | 1 |
| Boston, S; Hoddinott, K; Mutsaers, AJ; Oblak, ML; Wood, GA | 2 |
| Aizawa, M; Honda, M; Kameda, Y; Sato, T | 1 |
| Chen, L; Geng, H; Liu, L; Mei, C | 1 |
| Ding, Z; Feng, H; Feng, W; Li, J; Li, X; Tang, N; Wang, J; Wu, X; Zhang, P; Zhang, X; Zhao, Q | 1 |
| Fujiwara, T; Hasei, J; Kagawa, S; Komatsubara, T; Kunisada, T; Omori, T; Osaki, S; Ozaki, T; Sugiu, K; Tazawa, H; Uotani, K; Urata, Y; Yamakawa, Y; Yoshida, A | 1 |
| Koçer, G; Nazıroğlu, M; Övey, İS; Öz, A; Yazıcı, T | 1 |
| Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C | 1 |
| Açil, Y; Arndt, ML; Ayna, M; Gülses, A; Naujokat, H; Wieker, H; Wiltfang, J | 1 |
| Li, B; Li, H; Lin, N; Lin, P; Sun, L; Teng, W; Wang, S; Wang, Z; Xue, D; Ye, C; Ye, Z; Zhang, W; Zhou, X | 1 |
| Chen, P; Li, S; Pei, Y; Qiu, E; Wang, W; Zhang, X; Zheng, K | 1 |
| Dass, CR; Doschak, MR; Elahy, M; Friedhuber, AM; Hughes, JD; Wei, Y; Wong, JY | 1 |
| Anract, P; Bertucci, F; Blay, JY; Bompas, E; Brugieres, L; Collard, O; Cupissol, D; de Pinieux, G; Delaye, J; Duffaud, F; Italiano, A; Laurence, V; Le Cesne, A; Le Deley, MC; Occean, BV; Penel, N; Perrin, C; Piperno-Neumann, S; Ray-Coquard, I; Rios, M | 1 |
| Li, JJ; Li, S | 1 |
| Bernstein, M; Fan, TM; Goldsby, RE; Gorlick, R; Isakoff, MS; Kim, G; Krailo, M; Lee, S; Marina, N; Meyer, J; Randall, RL; Villaluna, D; Wagner, LM | 1 |
| Ando, T; Cates, JM; Cole, HA; Haro, H; Ohba, T; Schoenecker, JG; Schwartz, HS; Slosky, DA | 1 |
| Bevilacqua, N; Caraglia, M; Donnarumma, G; Galdiero, M; Lombardi, A; Misso, G; Rizzo, A | 1 |
| Baud'huin, M; Gleave, M; Guiho, R; Heymann, D; Lamoureux, F; Ory, B; Rédini, F; Zoubeidi, A | 1 |
| Li, BH; Li, HY; Li, YJ; Liu, M; Sun, LL; Ye, ZM; Zhang, J | 1 |
| Dai, K; Dass, CR; Li, H; Ouyang, Z; Qin, A; Xu, J; Zhai, Z | 1 |
| Amiaud, J; Battaglia, S; Baud'huin, M; Heymann, D; Lamoureux, F; Ory, B; Quillard, T; Redini, F; Royer, BB; Verrecchia, F | 1 |
| Cheng, HL; Hsieh, MJ; Lin, CW; Lu, KH; Yang, JS; Yang, SF | 1 |
| Aoyagi, T; Ichimura, S; Mochizuki, K; Morii, T; Ohnishi, H; Ohtsuka, K; Satomi, K; Tajima, T; Yoshiyama, A | 1 |
| Braun, A; Draenert, GF; Heymann, PG; Kämmerer, PW; Mandic, R; Neff, A; Saydali, A; Ziebart, T | 1 |
| Byrum, ML; Fan, TM; Fredrickson, RL; Pondenis, HC; Wycislo, KL | 1 |
| Fan, TM; Howes, ME; Lundberg, AP; Roady, PJ; Somrak, AJ | 1 |
| Blay, JY; Bompas, E; Bonnet, N; Brisse, H; Brugières, L; Chevance, A; Corradini, N; Entz-Werlé, N; Gentet, JC; Gomez-Brouchet, A; Gouin, F; Guinebretière, JM; Italiano, A; Le Deley, MC; Lervat, C; Marec-Bérard, P; Mascard, E; Pacquement, H; Penel, N; Petit, P; Piperno-Neumann, S; Rédini, F; Tabone, MD | 1 |
| Condon, KW; Curtis, RC; Custis, JT; Donahue, SW; Ehrhart, EJ; Ehrhart, NP; Gookin, SE | 1 |
| Jung, WG; Kim, EH; Kim, MS; Koh, JS; Kong, CB; Lee, KH | 1 |
| Chen, YL; Chueh, PJ; Hsieh, CP; Huang, YF; Wu, CC | 1 |
| Alexis, MN; Consoulas, C; Katopodis, H; Kletsas, D; Konstantinidou, E; Koutsilieris, M; Manoussakis, M; Pitulis, N; Poyatzi, A; Tenta, R; Tiblalexi, D | 1 |
| Baldi, A; Caruso, G; Citro, G; Santini, D; Spugnini, EP; Tonini, G; Vincenzi, B | 1 |
| Adachi, S; Fushiki, S; Horie, N; Kimura, S; Koto, K; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Sakabe, T; Watanabe, M | 1 |
| Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V; Ponomarev, V | 1 |
| Albert, JD; Chalès, G; Duval, H; El Mansouri, L; Guggenbuhl, P; Hajjaj-Hassouni, N; Meadeb, JM | 1 |
| Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V | 1 |
| Ashihara, E; Fushiki, S; Horie, N; Itoi, M; Kimura, S; Koto, K; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Nishigaki, Y; Ryu, K; Sakabe, T; Takeshita, H | 1 |
| Mochizuki, K; Morii, T; Ohnishi, H; Ohtsuka, K; Satomi, K | 1 |
| Battaglia, S; Blanchard, F; Brion, R; Charrier, C; Denis, MG; Heymann, D; Mitrofan, L; Mönkkönen, J; Moriceau, G; Ory, B; Pilet, P; Rédini, F; Riganti, C; Shultz, LD | 1 |
| Cao, ZG; Jiang, H; Li, ZX; Xu, Q; Yang, C; Ye, ZM | 1 |
| Hildreth, BE; Lanigan, LG; Martin, CK; Pillai, SP; Rosol, TJ; Werbeck, JL; Wolfe, TD | 1 |
| Battaglia, S; Chesneau, J; Corradini, N; Dumoucel, S; Gouin, F; Heymann, D; Heymann, MF; Picarda, G; Redini, F | 1 |
| Feng, X; Fu, D; He, X; Lin, T; Xu, W; Yang, S | 1 |
| Li, Z; Peng, H; Xu, Q; Ye, Z | 1 |
| Açil, Y; Gassling, V; Möller, B; Niehoff, P; Rachko, K; Simon, MJ; Wiltfang, J | 1 |
| Cheng, RL; Li, ZX; Sun, LL; Sun, ZW; Ye, ZM | 1 |
| Li, Z; Sun, L; Tang, J; Ye, Z | 1 |
| Bouralexis, S; Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A | 1 |
| Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP | 1 |
| Cortizo, AM; McCarthy, AD; Vaisman, DN | 1 |
| Gouin, F; Heymann, D; Heymann, MF; Kamijo, A; Ory, B; Redini, F | 1 |
| Arrich, F; Berger, W; Elbling, L; Heffeter, P; Kotz, R; Kubista, B; Micksche, M; Scotlandi, K; Sevelda, F; Sutterlüty, H; Toma, C; Trieb, K | 1 |
| Battaglia, S; Blanchard, F; Gouin, F; Heymann, D; Ory, B; Rédini, F | 1 |
| Benassi, MS; Chiechi, A; Ferrari, S; Gamberi, G; Manara, MC; Pazzaglia, L; Perego, P; Picci, P; Ponticelli, F; Zanella, L | 1 |
| Fushiki, S; Horie, N; Kimura, S; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Sakabe, T; Takeshita, H | 1 |
| Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Nakabayashi, C; Nakanishi, M; Saito, K; Saya, H | 1 |
| Battaglia, S; Duteille, F; Gouin, F; Heymann, D; Heymann, MF; Lamoureux, F; Ory, B; Pilet, P; Redini, F | 1 |
| Choong, PF; Dass, CR | 1 |
| Carraro, F; Fagioli, F; Madon, E; Mereuta, OM; Muraro, M | 1 |
| Berreur, M; Blanchard, F; Heymann, D; Moriceau, G; Ory, B; Rédini, F; Rogers, M; Trichet, V | 1 |
3 review(s) available for zoledronic acid and Osteosarcoma
| Article | Year |
|---|---|
Effects of zoledronic acid on osteosarcoma progression and metastasis: systematic review and meta-analysis.
Topics: Combined Modality Therapy; Humans; Osteosarcoma; Zoledronic Acid | 2023 |
New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Osteosarcoma; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2020 |
Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Differentiation; Cell Proliferation; Cell Survival; Humans; In Vitro Techniques; Lung Neoplasms; Osteosarcoma; Zoledronic Acid | 2018 |
6 trial(s) available for zoledronic acid and Osteosarcoma
| Article | Year |
|---|---|
Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Osteosarcoma; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2023 |
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Diphosphonates; Doxorubicin; Etoposide; Female; France; Humans; Ifosfamide; Imidazoles; Kaplan-Meier Estimate; Male; Methotrexate; Neutropenia; Osteosarcoma; Young Adult; Zoledronic Acid | 2018 |
Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Methotrexate; Middle Aged; Osteosarcoma; Survival Rate; Zoledronic Acid | 2019 |
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; France; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Prognosis; Survival Rate; Young Adult; Zoledronic Acid | 2020 |
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Edema; Extremities; Feasibility Studies; Female; Humans; Hypokalemia; Hyponatremia; Hypophosphatemia; Imidazoles; Kaplan-Meier Estimate; Male; Mucositis; Neoplasm Metastasis; Osteosarcoma; Pain; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Studies; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Diphosphonates; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Imidazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Osteosarcoma; Prognosis; Survival Rate; Young Adult; Zoledronic Acid | 2016 |
60 other study(ies) available for zoledronic acid and Osteosarcoma
| Article | Year |
|---|---|
CORR Insights®: Does Local Zoledronate Applied to Pasteurized Bone Autografts Improve the Likelihood of Union of Graft-Host Junctions after Limb-sparing Surgery?
Topics: Autografts; Bone Neoplasms; Bone Transplantation; Humans; Osteosarcoma; Zoledronic Acid | 2022 |
Fracture rate and time to fracture in dogs with appendicular osteosarcoma receiving finely fractionated compared to coarsely fractionated radiation therapy: A single institution study.
Topics: Animals; Bone Neoplasms; Dog Diseases; Dogs; Fractures, Spontaneous; Humans; Osteosarcoma; Retrospective Studies; Zoledronic Acid | 2022 |
Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
Topics: Bone Neoplasms; CD28 Antigens; Diphosphonates; Humans; Imidazoles; Leukocytes, Mononuclear; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2022 |
Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma.
Topics: Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Ferroptosis; Humans; Imidazoles; Osteosarcoma; Quality of Life; Reactive Oxygen Species; Zoledronic Acid | 2023 |
A colloidal hydrogel-based drug delivery system overcomes the limitation of combining bisphosphonates with bioactive glasses: in vitro evidence of a potential selective bone cancer treatment allied with bone regeneration.
Topics: Bone Neoplasms; Bone Regeneration; Diphosphonates; Drug Delivery Systems; Humans; Hydrogels; Osteosarcoma; Tumor Microenvironment; Zoledronic Acid | 2023 |
Polymeric Nanoformulation of Zoledronic Acid Rescues Osteoblasts from the Harmful Effect of its Native Form: An In Vitro Investigation of Cytotoxic Potential on Osteoblasts and Osteosarcoma Cells.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Delayed-Action Preparations; Diphosphonates; Humans; Imidazoles; Mice; Osteoblasts; Osteosarcoma; Zoledronic Acid | 2023 |
Effect of timing of bisphosphonate administration on canine osteosarcoma cells undergoing radiation therapy.
Topics: Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Dog Diseases; Dogs; Drug Administration Schedule; Osteosarcoma; Pamidronate; Zoledronic Acid | 2020 |
Zoledronic Acid-Loaded β-TCP Inhibits Tumor Proliferation and Osteoclast Activation: Development of a Functional Bone Substitute for an Efficient Osteosarcoma Treatment.
Topics: Animals; Bone Substitutes; Calcium Phosphates; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Drug Liberation; Humans; Male; Mesenchymal Stem Cells; Mice, Inbred C57BL; Osteoclasts; Osteosarcoma; Zoledronic Acid | 2021 |
Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Drug Synergism; Humans; Mice; Mice, Nude; Osteolysis; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2021 |
A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Liberation; Erythrocyte Membrane; Humans; Metal-Organic Frameworks; Mice, Inbred BALB C; Mice, Nude; Osteolysis; Osteosarcoma; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2021 |
Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Combined Modality Therapy; Diphosphonates; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Mice; Mice, Nude; Oncolytic Virotherapy; Osteoclasts; Osteosarcoma; RANK Ligand; RAW 264.7 Cells; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment.
Topics: Apoptosis; Bevacizumab; Calcium; Cell Line, Tumor; Dexamethasone; Diphosphonates; Humans; Imidazoles; Mitochondria; Osteosarcoma; Oxidative Stress; Pharmaceutical Preparations; Protective Agents; Reactive Oxygen Species; Selenium; TRPV Cation Channels; Zoledronic Acid | 2018 |
Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Topics: Alendronate; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Cytotoxins; Diphosphonates; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression; Gingiva; Humans; Imidazoles; Inflammation; Osteoblasts; Osteosarcoma; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2018 |
Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Humans; Immunotherapy; Lymphocyte Activation; Mevalonic Acid; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; Signal Transduction; T-Lymphocytes; Valproic Acid; Zoledronic Acid | 2018 |
Evaluation of effects of radiation therapy combined with either pamidronate or zoledronate on canine osteosarcoma cells.
Topics: Animals; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Osteosarcoma; Pamidronate; Tumor Stem Cell Assay; Zoledronic Acid | 2019 |
Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin.
Topics: Animals; Apoptosis; Bone Neoplasms; Cardiotonic Agents; Caspase 2; Cell Cycle; Cell Line, Tumor; Doxorubicin; Enzyme Activation; Eye Proteins; Fetus; Humans; Mice, Inbred BALB C; Nerve Growth Factors; Osteosarcoma; Serpins; Zoledronic Acid | 2019 |
Zoledronic acid modulates human osteosarcoma cells proliferation via GSK-3β activation.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Glycogen Synthase Kinase 3 beta; Humans; Osteosarcoma; Signal Transduction; Zoledronic Acid | 2019 |
Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Topics: Animals; Bone Resorption; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Diphosphonates; Humans; Imidazoles; Mice; Monocytes; Neoplasm Invasiveness; Osteoclasts; Osteogenesis; Osteolysis; Osteoprotegerin; Osteosarcoma; RANK Ligand; Zoledronic Acid | 2014 |
Zoledronic acid affects the cytotoxic effects of Chlamydia pneumoniae and the modulation of cytokine production in human osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Chlamydophila Infections; Chlamydophila pneumoniae; Cytokines; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunity, Innate; Immunomodulation; Inflammation Mediators; Osteosarcoma; Up-Regulation; Zoledronic Acid | 2014 |
Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clusterin; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Mice; Mice, Nude; Osteosarcoma; Reverse Transcriptase Polymerase Chain Reaction; Thionucleotides; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Osteosarcoma; Receptor, ErbB-2; T-Lymphocytes, Cytotoxic; Trastuzumab; Zoledronic Acid | 2015 |
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Mice; Mice, Nude; Monocytes; Neoplasm Metastasis; Osteosarcoma; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
Topics: Biological Transport; Bone Density Conservation Agents; Bone Neoplasms; Cadherins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Diterpenes; Epithelial-Mesenchymal Transition; Farnesol; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasm Invasiveness; Nuclear Proteins; Osteoporosis; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prenylation; Proto-Oncogene Proteins pp60(c-src); rho-Associated Kinases; Snail Family Transcription Factors; Twist-Related Protein 1; Zoledronic Acid | 2016 |
Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
The enhancing effect of a laser photochemotherapy with cisplatin or zolendronic acid in primary human osteoblasts and osteosarcoma cells in vitro.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Cisplatin; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Osteoblasts; Osteosarcoma; Zoledronic Acid | 2016 |
Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dog Diseases; Dogs; Female; Gene Expression Regulation, Neoplastic; Imidazoles; Male; Neoplasm Metastasis; Osteosarcoma; Receptors, CXCR4; Zoledronic Acid | 2016 |
Zoledronate-Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Dog Diseases; Dogs; Imidazoles; Male; Osteosarcoma; Zoledronic Acid | 2016 |
Combination Therapy with Zoledronic Acid and Parathyroid Hormone Improves Bone Architecture and Strength following a Clinically-Relevant Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine Osteosarcoma in Athymic Rats.
Topics: Animals; Bone and Bones; Calcification, Physiologic; Combined Modality Therapy; Diphosphonates; Dogs; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Female; Imidazoles; Luminescence; Osteosarcoma; Parathyroid Hormone; Rats, Nude; Stereotaxic Techniques; Tartrate-Resistant Acid Phosphatase; Time Factors; X-Ray Microtomography; Zoledronic Acid | 2016 |
Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Diphosphonates; DNA Damage; DNA Repair; Epithelial-Mesenchymal Transition; Female; Gamma Rays; Humans; Imidazoles; Immunohistochemistry; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Radiation Dosage; Radiation-Sensitizing Agents; Reactive Oxygen Species; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Imidazoles; Osteosarcoma; Oxidative Stress; Reactive Oxygen Species; Triterpenes; Ursolic Acid; Zoledronic Acid | 2016 |
Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells.
Topics: Aniline Compounds; Apoptosis; Calcium; Cell Differentiation; Cell Division; Cell Line, Tumor; Diphosphonates; Doxorubicin; Edetic Acid; Flow Cytometry; Fluorescent Dyes; G1 Phase; Humans; Imidazoles; Osteosarcoma; Polyisoprenyl Phosphates; ras Proteins; Receptors, Estrogen; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; Sesquiterpenes; Xanthenes; Zoledronic Acid | 2008 |
Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Dog Diseases; Dogs; Euthanasia, Animal; Forelimb; Imidazoles; Lameness, Animal; Lymph Node Excision; Lymphatic Metastasis; Male; Osteosarcoma; Radiography; Zoledronic Acid | 2009 |
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
Topics: Animals; Cell Proliferation; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Lung Neoplasms; Mice; Osteosarcoma; Protein Prenylation; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Female; Green Fluorescent Proteins; Humans; Imidazoles; Luciferases; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Osteolysis; Osteosarcoma; Recombinant Fusion Proteins; Tibia; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Bifocal sarcomatous transformation of Paget's disease: a case report.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Transformation, Neoplastic; Diphosphonates; Humans; Imidazoles; Male; Osteitis Deformans; Osteosarcoma; Pleural Effusion; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2009 |
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Caspases; Cell Proliferation; Diphosphonates; Imidazoles; Lung Neoplasms; Male; Osteosarcoma; Rats; Rats, Inbred F344; Zoledronic Acid | 2010 |
Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Imidazoles; Mice; Osteosarcoma; Zoledronic Acid | 2010 |
Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Immunoblotting; Osteosarcoma; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Zoledronic Acid | 2010 |
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Osteosarcoma; Protein Prenylation; ras Proteins; Rats; Sirolimus; TOR Serine-Threonine Kinases; Zoledronic Acid | 2010 |
[gammadelta T cells stimulated by zoledronate kill osteosarcoma cells].
Topics: Animals; Cell Death; Cell Line, Tumor; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Mice; Osteosarcoma; T-Lymphocytes; Zoledronic Acid | 2010 |
Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Dog Diseases; Dogs; Female; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2011 |
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.
Topics: Animals; Bone Development; Bone Neoplasms; Child; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Mice, Inbred C57BL; Osteosarcoma; Zoledronic Acid | 2011 |
Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro.
Topics: Angiogenesis Inhibitors; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Imidazoles; Mice; Microvilli; Neovascularization, Pathologic; Organ Culture Techniques; Osteosarcoma; Protein Transport; rhoA GTP-Binding Protein; Zoledronic Acid | 2011 |
Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
Topics: Adolescent; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Child; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interferon-gamma; Male; Osteosarcoma; Perforin; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; TNF-Related Apoptosis-Inducing Ligand; Young Adult; Zoledronic Acid | 2012 |
The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.
Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Collagen Type I; Coloring Agents; Diphosphates; Diphosphonates; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Follow-Up Studies; Gingiva; Humans; Imidazoles; Osteoblasts; Osteocalcin; Osteosarcoma; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid | 2012 |
[Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Interleukin-2; Leukocytes, Mononuclear; Lymphocyte Activation; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2012 |
[Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cytotoxicity, Immunologic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2013 |
Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Topics: Anoikis; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Caspases; Cell Adhesion; Cell Division; Cell Line, Tumor; Cholesterol; Diphosphonates; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Imidazoles; Osteosarcoma; Zoledronic Acid | 2003 |
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Fibrosis; Ifosfamide; Imidazoles; Male; Necrosis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Osteoblasts; Osteogenesis; Osteosarcoma; Rats; Rats, Sprague-Dawley; S Phase; Survival Rate; Tibia; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2005 |
Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Cations, Divalent; Diphosphonates; Imidazoles; Isoenzymes; Magnesium; Osteoblasts; Osteosarcoma; Pamidronate; Rats; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2005 |
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred C3H; Osteosarcoma; Survival Analysis; Zoledronic Acid | 2005 |
Anticancer effects of zoledronic acid against human osteosarcoma cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclins; Diphosphonates; DNA; DNA Replication; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Farnesol; Humans; Imidazoles; Osteosarcoma; Protein Prenylation; Terpenes; Zoledronic Acid | 2006 |
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Topics: Animals; Apoptosis Inducing Factor; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Diphosphonates; DNA, Neoplasm; Endodeoxyribonucleases; Humans; Imidazoles; Microscopy, Confocal; Osteosarcoma; Protein Transport; Rats; S Phase; Tumor Suppressor Protein p53; Zoledronic Acid | 2007 |
Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Cisplatin; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Osteosarcoma; Retinoblastoma Protein; RNA, Small Interfering; Tumor Suppressor Protein p53; Zoledronic Acid | 2007 |
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Division; Diphosphonates; Drug Therapy, Combination; Imidazoles; Mice; Osteosarcoma; Zoledronic Acid | 2007 |
Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bone Density Conservation Agents; Bone Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Diphosphonates; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Imidazoles; Osteosarcoma; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Tumor Suppressor Proteins; Zoledronic Acid | 2007 |
Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Marrow Cells; Bone Neoplasms; Bone Remodeling; Cell Cycle; Cell Proliferation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Osteoblasts; Osteogenesis; Osteosarcoma; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Zoledronic Acid | 2008 |
Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.
Topics: Animals; Base Sequence; Bone Density Conservation Agents; Cell Division; Cell Line, Tumor; Diphosphonates; DNA Primers; Humans; Imidazoles; Mice; Neoplasm Transplantation; Osteoclasts; Osteosarcoma; Zoledronic Acid | 2007 |
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Immunotherapy; Osteosarcoma; Receptors, Antigen, T-Cell, gamma-delta; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; Zoledronic Acid | 2007 |
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Geranyltranstransferase; Humans; Imidazoles; Male; Middle Aged; Osteosarcoma; RNA, Small Interfering; Time Factors; Transfection; Zoledronic Acid | 2008 |